secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001104659-26-001957
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS Life Sciences estimates $71.8M cash at Dec 31, 2025; $26.5M from warrant exercises post-quarter
--------------------------------------------------------------------------------

- Cash and cash equivalents estimate of $71.8M as of Dec 31, 2025 (unaudited, preliminary).
- Received ~$26.5M in proceeds from common stock warrant exercises subsequent to year-end.
- As of Jan 7, 2026, shares outstanding total 170,282,026.
- No other operational or financial results disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000110465926001957/0001104659-26-001957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000110465926001957/tm262494d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-001957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer